Expression of the Transmembrane Glycoprotein CD44s Is Potentially an Independent Predictor of Recurrence in Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Cluster differentiation 44 standard isoform (CD44s) is a transmembrane glycoprotein. CD44s is a known prognostic factor in various cancers, due to its involvement in tumor cell growth, invasion and metastasis. Its prognostic role, however, is debated because it can be a positive or negative prognostic factor depending on tumor type and is still an ambiguous prognostic indicator in other cancers,especially hepatocellular carcinoma (HCC). We investigated the relationship between CD44s expression and survival in HCC patients. Methods: A total of 260 HCC samples were collected to generate a tissue microarray. Staining of the arrays with a primary mouse CD44s monoclonal antibody was followed by evaluation of the relationship between CD44s expression and tumor differentiation. The effect of CD44s expression on patient survival was analyzed. Results: CD44s protein expression correlated with histological grade (most and worst Edmondson grade) of the HCC (p=0.029 and p=0.039, respectively) and adversely affected the disease free survival period based on univariate and multivariate analyses (p=0.038 and p=0.077, respectively). Conclusions:High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44stargeted therapy may be effi cacious for HCC treatment in the future.
Abstract
Background/Aims: Cluster differentiation 44 standard isoform (CD44s) is a transmembrane glycoprotein. CD44s is a known prognostic factor in various cancers, due to its involvement in tumor cell growth, invasion and metastasis. Its prognostic role, however, is debated because it can be a positive or negative prognostic factor depending on tumor type and is still an ambiguous prognostic indicator in other cancers,especially hepatocellular carcinoma (HCC). We investigated the relationship between CD44s expression and survival in HCC patients. Methods: A total of 260 HCC samples were collected to generate a tissue microarray. Staining of the arrays with a primary mouse CD44s monoclonal antibody was followed by evaluation of the relationship between CD44s expression and tumor differentiation. The effect of CD44s expression on patient survival was analyzed. Results: CD44s protein expression correlated with histological grade (most and worst Edmondson grade) of the HCC (p=0.029 and p=0.039, respectively) and adversely affected the disease free survival period based on univariate and multivariate analyses (p=0.038 and p=0.077, respectively). Conclusions:High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44stargeted therapy may be effi cacious for HCC treatment in the future.
참고문헌 (27)
- Parkin DM, "The global health burden of infection-associated cancers in the year 2002", Int J Cancer, 118, pp.3030~3044 (2006)
- Tölg C, "Splicing choice from ten variant exons establishes CD44 variability", Nucleic Acids Res, 21, pp.1225~1229 (1993)
- Naor D, "CD44: structure, function, and association with the malignant process", Adv Cancer Res, 71, pp.241~319 (1997)
- Fox SB, "Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms", Cancer Res, 54, pp.4539~4546 (1994)
- Mackay CR, "Expression and modulation of CD44 variant isoforms in humans", J Cell Biol, 124, pp.71~82 (1994)
- Naor D, "CD44 in cancer", Crit Rev Clin Lab Sci, 39, pp.527~579 (2002)
- Ponta H, "The CD44 protein family", Int J Biochem Cell Biol, 30, pp.299~305 (1998)
- Gilcrease MZ, "Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence", Cancer, 86, pp.2320~2326 (1998)
- Böhm JP, "Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma", J Pathol, 192, pp.321~327 (2000)
- 허정욱, "Expression of standard CD44 in human colorectal carcinoma: Association with prognosis", PATHOLOGY INTERNATIONAL, 59(4), pp.241~246, WILEY-BLACKWELL PUBLISHING
- Heyse TJ, "CD44: survival and metastasis in chondrosarcoma", Osteoarthritis Cartilage, 18, pp.849~856 (2010)
- Gunia S, "Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameters", Pathobiology, 76, pp.286~282 (2009)
- Mathew J, "CD44 is expressed in hepatocellular carcinomas showing vascular invasion", J Pathol, 179, pp.74~79 (1996)
- Endo K, "Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival", J Hepatol, 32, pp.78~84 (2000)
- Edmondson HA, "Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies", Cancer, 7, pp.462~503 (1954)
- Lee TK, "Liver cancer stem cells: implications for a new therapeutic target", Liver Int, 29, pp.955~965 (2009)
- Zhu Z, "Cancer stem", progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma, 2010, pp.126, 2067~2078
- Al-Hajj M, "Prospective identification of tumorigenic breast cancer cells", Proc Natl Acad Sci U S A, 100, pp.3983~3988 (2003)
- Beckebaum S, "Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection", Transplant Proc, 40, pp.3182~3184 (2008)
- Gao C, "Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells", Carcinogenesis, 24, pp.1871~1878 (2003)
- Zhang P, "Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma", Clin Cancer Res, 12, pp.6617~6625 (2006)
- Kuncová J, "Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells", APMIS, 115, pp.1194~1205 (2007)
- Bendardaf R, "Comparison of CD44 expression in primary tumours and metastases of colorectal cancer", Oncol Rep, 16, pp.741~746 (2006)
- Yang GH, "Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection", Oncologist, 13, pp.1155~1165 (2008)
- Daniele B, "Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma", Gastroenterology, 127(5 Suppl 1), pp.S108~S112 (2004)
- Gunia S, "CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma", Clin Exp Metastasis, 17, pp.221~230 (1999)
- Breyer R, "Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti- CD44 monoclonal antibody", J Neurosurg, 92, pp.140~149 (2000)